DK1910381T3 - Substituerede 1-oxa-3,8-diazaspiro[4,5]-dekan-2-on-forbindelser og anvendelse af disse til fremstilling af lægemidler - Google Patents

Substituerede 1-oxa-3,8-diazaspiro[4,5]-dekan-2-on-forbindelser og anvendelse af disse til fremstilling af lægemidler

Info

Publication number: DK1910381T3
Authority: DK; Denmark
Prior art keywords: gen; substituted; compounds; optionally substituted; definitions
Prior art date: 2005-06-27

Application number

DK06754597T

Other languages

English (en)

Inventor

Michael Przewosny

Sundermann Corinna Dr

Sundermann Bernd Dr

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-27

Filing date

2006-06-27

Publication date

2009-10-05

2006-06-27 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2009-10-05 Application granted granted Critical

2009-10-05 Publication of DK1910381T3 publication Critical patent/DK1910381T3/da

Links

LQGLKWIXYWZNGB-UHFFFAOYSA-N 1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical class O1C(=O)NCC11CCNCC1 LQGLKWIXYWZNGB-UHFFFAOYSA-N 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
-1 racemates Chemical class 0.000 abstract 2
108091006082 receptor inhibitors Proteins 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
230000013275 serotonin uptake Effects 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
125000001931 aliphatic group Chemical group 0.000 abstract 1
230000001195 anabolic effect Effects 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000000954 anitussive effect Effects 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
230000002075 anti-alcohol Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002460 anti-migrenic effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
230000001139 anti-pruritic effect Effects 0.000 abstract 1
230000002738 anti-smoking effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
239000003908 antipruritic agent Substances 0.000 abstract 1
229940124584 antitussives Drugs 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
238000004166 bioassay Methods 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
229940121354 immunomodulator Drugs 0.000 abstract 1
230000002584 immunomodulator Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
239000003176 neuroleptic agent Substances 0.000 abstract 1
230000000701 neuroleptic effect Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
230000012154 norepinephrine uptake Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pulmonology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK06754597T 2005-06-27 2006-06-27 Substituerede 1-oxa-3,8-diazaspiro[4,5]-dekan-2-on-forbindelser og anvendelse af disse til fremstilling af lægemidler DK1910381T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102005030051A DE102005030051A1 (de)	2005-06-27	2005-06-27	Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PCT/EP2006/006215 WO2007000325A2 (de)	2005-06-27	2006-06-27	Substituierte 1-oxa-3,8-diazaspiro[4.5]-decan-2-on-verbindungen und deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number	Publication Date
DK1910381T3 true DK1910381T3 (da)	2009-10-05

Family

ID=37513646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06754597T DK1910381T3 (da)	2005-06-27	2006-06-27	Substituerede 1-oxa-3,8-diazaspiro[4,5]-dekan-2-on-forbindelser og anvendelse af disse til fremstilling af lægemidler

Country Status (13)

Country	Link
US (1)	US8153795B2 (da)
EP (1)	EP1910381B1 (da)
JP (1)	JP5237094B2 (da)
AT (1)	ATE432938T1 (da)
CA (1)	CA2613874C (da)
CY (1)	CY1109339T1 (da)
DE (2)	DE102005030051A1 (da)
DK (1)	DK1910381T3 (da)
ES (1)	ES2328278T3 (da)
PL (1)	PL1910381T3 (da)
PT (1)	PT1910381E (da)
SI (1)	SI1910381T1 (da)
WO (1)	WO2007000325A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010517967A (ja) *	2007-02-01	2010-05-27	グラクソグループリミテッド	摂食障害の治療のための１−オキサ−３−アザスピロ［４，５］デカン−２−オン誘導体
EP2121673A1 (en) *	2007-02-01	2009-11-25	Glaxo Group Limited	I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
US7977358B2 (en)	2007-07-26	2011-07-12	Hoffmann-La Roche Inc.	Pyrazol derivatives
TW200944520A (en) *	2008-01-29	2009-11-01	Glaxo Group Ltd	Spiro compounds as NPY Y5 receptor antagonists
AU2010207486B2 (en) *	2009-01-26	2013-03-07	Israel Institute For Biological Research	Bicyclic heterocyclic spiro compounds
TW201038572A (en) *	2009-03-25	2010-11-01	Gruenenthal Gmbh	Substituted spiro-amide compounds
US8492591B2 (en)	2010-02-04	2013-07-23	The Board Of Trustees Of The University Of Illinois	Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR101799429B1 (ko)	2010-05-03	2017-11-21	에스케이바이오팜 주식회사	신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
ES2716049T3 (es)	2012-07-13	2019-06-07	Pain Therapeutics Inc	Un método para inhibir la fosforilación de tau
JP6566867B2 (ja)	2012-07-13	2019-08-28	ペインセラピューティクスインコーポレイテッド	生きている患者でのアルツハイマー病アッセイ
US10092574B2 (en)	2012-09-26	2018-10-09	Valorisation-Recherche, Limited Partnership	Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
US9433604B2 (en)	2013-10-08	2016-09-06	Pain Therapeutics Inc.	Method for inhibiting growth of cancer cells
TW201615642A (zh)	2014-06-02	2016-05-01	伊史帝夫博士實驗室股份有限公司	具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh)	2014-06-02	2020-02-21	西班牙商伊史帝夫製藥公司	具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh)	2014-06-02	2016-05-01	伊史帝夫博士實驗室股份有限公司	具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
ME03636B (me)	2015-10-23	2020-07-20	Esteve Pharmaceuticals Sa	Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola
AR106697A1 (es)	2015-11-16	2018-02-07	Esteve Labor Dr	Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas
EP3722284B1 (en)	2016-01-13	2025-01-22	Grünenthal GmbH	3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
JP6854823B2 (ja)	2016-01-13	2021-04-07	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	３−（カルボキシメチル）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
SI3402782T1 (sl)	2016-01-13	2020-11-30	Grunenthal Gmbh	8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
MY200894A (en)	2017-10-17	2024-01-22	Esteve Pharmaceuticals Sa	Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
KR20240102969A (ko) *	2021-10-13	2024-07-03	밴쿠아 바이오, 인크.	글루코세레브로시다제 활성의 소분자 조절제 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH601304A5 (da) *	1974-02-12	1978-07-14	Buskine Sa
US4244961A (en) *	1978-10-26	1981-01-13	Syntex (U.S.A.) Inc.	1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4255432A (en) *	1979-09-06	1981-03-10	Syntex (U.S.A.) Inc.	8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US5739336A (en) *	1995-06-23	1998-04-14	Syntex (U.S.A.) Inc.	1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
EP1087770A4 (en) *	1998-06-15	2001-11-14	Merck & Co Inc	PRENYL PROTEIN TRANSFERASE INHIBITORS
MXPA04006280A (es)	2001-12-28	2004-09-27	Acadia Pharm Inc	Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
US6995144B2 (en) *	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same

2005
- 2005-06-27 DE DE102005030051A patent/DE102005030051A1/de not_active Withdrawn
2006
- 2006-06-27 SI SI200630388T patent/SI1910381T1/sl unknown
- 2006-06-27 US US11/994,001 patent/US8153795B2/en not_active Expired - Fee Related
- 2006-06-27 PT PT06754597T patent/PT1910381E/pt unknown
- 2006-06-27 AT AT06754597T patent/ATE432938T1/de active
- 2006-06-27 JP JP2008518705A patent/JP5237094B2/ja not_active Expired - Fee Related
- 2006-06-27 WO PCT/EP2006/006215 patent/WO2007000325A2/de not_active Ceased
- 2006-06-27 PL PL06754597T patent/PL1910381T3/pl unknown
- 2006-06-27 ES ES06754597T patent/ES2328278T3/es active Active
- 2006-06-27 CA CA2613874A patent/CA2613874C/en not_active Expired - Fee Related
- 2006-06-27 DK DK06754597T patent/DK1910381T3/da active
- 2006-06-27 EP EP06754597A patent/EP1910381B1/de not_active Not-in-force
- 2006-06-27 DE DE502006003897T patent/DE502006003897D1/de active Active
2009
- 2009-09-01 CY CY20091100917T patent/CY1109339T1/el unknown

Also Published As

Publication number	Publication date
EP1910381B1 (de)	2009-06-03
CA2613874C (en)	2013-12-17
JP5237094B2 (ja)	2013-07-17
PL1910381T3 (pl)	2009-11-30
CA2613874A1 (en)	2007-01-04
JP2008546820A (ja)	2008-12-25
ES2328278T3 (es)	2009-11-11
CY1109339T1 (el)	2014-07-02
PT1910381E (pt)	2009-09-09
US8153795B2 (en)	2012-04-10
SI1910381T1 (sl)	2009-12-31
ATE432938T1 (de)	2009-06-15
WO2007000325A2 (de)	2007-01-04
DE502006003897D1 (de)	2009-07-16
WO2007000325A3 (de)	2007-04-19
US20090105290A1 (en)	2009-04-23
DE102005030051A1 (de)	2006-12-28
EP1910381A2 (de)	2008-04-16

Publication	Publication Date	Title
CY1109339T1 (el)	2014-07-02	Υποκατεστημενες ενωσεις 1-οξα-3,8-διαζασπειρο[4.5]-δεκαν-2-ονης και η χρησιμοποιηση τους για την παρασκευη φαρμακων
UA85576C2 (ru)	2009-02-10	Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
MA29136B1 (fr)	2008-01-02	Agents de potentialisation de recepteurs du glutamate
TR201821273T4 (tr)	2019-01-21	Cis-tetrahidro-spiro(sikloheksan-1,1'-pirido [3,4-b] indol)-4-amin türevleri.
CY1109722T1 (el)	2014-04-09	Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
EA201070091A1 (ru)	2010-06-30	Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
AR047681A1 (es)	2006-02-01	Compuestos indazol-carboxamida como agonistas del receptor 5-ht4
UA95469C2 (ru)	2011-08-10	Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применения в терапии
DE602006006850D1 (de)	2009-06-25	Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
SE0403171D0 (sv)	2004-12-23	New compounds
EP1814913A4 (en)	2008-09-03	ANTIBODY-INDUCED CELL MEMBRANE INJURY
ATE523519T1 (de)	2011-09-15	Makrolidverbindungen mit biotin und fotoaffinitätsgruppe zur identifizierung eines makrolid-targets
FR2945457B1 (fr)	2011-07-15	Ensemble forme d'une membrane de filtration et d'une plaque de support, ainsi que dispositif de test microbiologique en faisant usage.
TNSN07015A1 (en)	2008-06-02	Kynurenic acid amide derivatives as nr2b receptor antagonists
TW200736227A (en)	2007-10-01	New compounds III
DE602004009030D1 (de)	2007-10-31	Phenyltetrazol-Verbindungen
DE502008002059D1 (de)	2011-02-03	Verwendung amphoterer Ionenaustauscher
ATE486071T1 (de)	2010-11-15	Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
PL1968900T3 (pl)	2011-09-30	Beztlenowe oczyszczenie ścieków
CR11084A (es)	2010-01-21	Compuesto biciclico y uso farmaceutico del mismo
SE0402284D0 (sv)	2004-09-21	New heterocyclic amides
DK1893620T3 (da)	2012-01-16	Substituerede spiroforbindelser og disses anvendelse til fremstilling af smertestillende lægemidler
DOP2005000259A (es)	2006-11-15	Compuesto químico y su uso.
EA200700550A1 (ru)	2007-10-26	Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
TW200720262A (en)	2007-06-01	Novel compounds ii